FDA approves subcutaneous Leqembi for Alzheimer’s initiation
Food and Drug Administration approved a supplemental Biologics License Application for once-weekly lecanemab subcutaneous injection as a starting dose for early Alzheimer’s disease treatment, BioArctic AB (Nasdaq Stockholm:BIOA B) announced in a press release statement Sunday. The approval allows Eisai to launch Leqembi Iqlik in late August 2026.
Reported by 1 outlet — Investing.com · Company News. See all sources ↓
Food and Drug Administration approved a supplemental Biologics License Application for once-weekly lecanemab subcutaneous injection as a starting dose for early Alzheimer’s disease treatment, BioArctic AB (Nasdaq Stockholm:BIOA B) announced in a press release statement Sunday. The approval allows Eisai to launch Leqembi Iqlik in late August 2026. The treatment is administered via autoinjector at 500 mg once weekly, delivered as two 250 mg injections of approximately 15 seconds each. Leqembi Iqlik was previously approved in the U.S.
Read the full report at Investing.com · Company News ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- Food and Drug Administration approved a supplemental Biologics License Application for once-weekly lecanemab subcutaneous injection as a starting dose for early Alzheimer’s disease treatment, BioArctic AB (Nasdaq Stockholm:BIOA B) announced in a press release statement Sunday. The approval allows Eisai to launch Leqembi Iqlik in late August 2026.
- How widely is it covered?
- 1 outlet, average source rating 5.0/10.
- When was it last updated?
- 8m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
FDA approves subcutaneous Leqembi for Alzheimer’s initiation
Sources1TypeCoverageInvesting.com · Company News